Markets
NVS

Novartis Receives Positive CHMP Opinion For Mayzent To Treat SPMS

(RTTNews) - Novartis (NVS) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA adopted a positive opinion for Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis or SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

It is estimated that up to 80% of patients will eventually transition from relapsing remitting multiple sclerosis or RRMS to secondary progressive multiple sclerosis or SPMS.

CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVS

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More